An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients.

@article{Sveikata2011AnOM,
  title={An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients.},
  author={Audrius Sveikata and Sigita Liutkauskiene and Elona Juozaitytė and Dainius Characiejus and Laimutė Tamo{\vs}aitytė and Kastytis {\vS}e{\vs}takauskas},
  journal={Medicina},
  year={2011},
  volume={47 8},
  pages={
          428-33
        }
}
UNLABELLED The primary objective of this open-label, two chemotherapy arm, phase 4 study was to evaluate the safety and efficacy of newly developed recombinant granulocyte colony-stimulating factor (rG-CSF) used to prevent neutropenia-related complications in patients with metastatic breast cancer treated with docetaxel (75 mg/m(2)) and doxorubicin (50 mg/m(2)) or docetaxel (100 mg/m(2)) alone. MATERIAL AND METHODS A total of 50 patients who were treated with a maximum of 6 cycles of either… CONTINUE READING